UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 73

Sortiert nach

Androgen Receptor Expression and Outcomes in Early Breast Cancer: A Systematic Review and Meta-Analysis

JNCI : Journal of the National Cancer Institute, 2014-01, Vol.106 (1), p.djt319-djt319

2014

Volltextzugriff (PDF)

How valid are claims for synergy in published clinical studies?

Annals of oncology, 2012-08, Vol.23 (8), p.2161-2166

2012

Volltextzugriff (PDF)

Hyperglycaemia and Survival in Solid Tumours: A Systematic Review and Meta-analysis

Clinical oncology (Royal College of Radiologists (Great Britain)), 2018-04, Vol.30 (4), p.215-224

2018

Volltextzugriff (PDF)

Evolution in the eligibility criteria of randomized controlled trials for systemic cancer therapies

Cancer treatment reviews, 2016-02, Vol.43, p.67-73

2016

Volltextzugriff (PDF)

Medical Oncology Workload in Europe: One Continent, Several Worlds

Clinical oncology (Royal College of Radiologists (Great Britain)), 2020-01, Vol.32 (1), p.e19-e26

2020

Volltextzugriff (PDF)

Magnitude of clinical benefit in trials supporting US Food and Drug Administration (FDA) accelerated approval (AA) and European Medicines Agency (EMA) conditional marketing authorisation (CMA) and subsequent trials supporting conversion to full approval

Annals of oncology, 2018-10, Vol.29, p.viii564-viii564

2018

Volltextzugriff (PDF)

A multimodal approach for the management of co-morbid cardiotoxicity in the elderly breast cancer patients

EUROPEAN JOURNAL OF CANCER, 2022, Vol.175, p.S40

2022

Volltextzugriff (PDF)

Medical oncology workload in Canada: infrastructure, supports, and delivery of clinical care

Current oncology (Toronto), 2018-06, Vol.25 (3), p.206-212

2018

Volltextzugriff (PDF)

1229 Industry-Sponsored Posters at Major Oncology Conferences: Science or Marketing?

European journal of cancer (1990), 2015-09, Vol.51, p.S183-S183

2015

Volltextzugriff (PDF)

Association of Aromatase Inhibitors With Coronary Heart Disease in Women With Early Breast Cancer

Cancer investigation, 2014-05, Vol.32 (4), p.99-104

2014

Volltextzugriff (PDF)

Comparison of absolute benefits of anticancer therapies determined by snapshot and area methods

Annals of oncology, 2012-11, Vol.23 (11), p.2977-2982

2012

Volltextzugriff (PDF)

1204 Influence of companion diagnostics on efficacy and safety of targeted anti-cancer drugs

European journal of cancer (1990), 2015-09, Vol.51, p.S172-S173

2015

Volltextzugriff (PDF)

1215 Role of cooperative groups and funding source in clinical studies that support approved therapy for breast cancer

European journal of cancer (1990), 2015-09, Vol.51, p.S176-S177

2015

Volltextzugriff (PDF)

2589 Adjuvant radiation therapy after radical nephrectomy in patients with localized renal cell carcinoma: a systematic review and meta-analysis

European journal of cancer (1990), 2015-09, Vol.51, p.S508-S508

2015

Volltextzugriff (PDF)

1973 Epidermal growth factor receptor (EGFR) over-expression and outcomes in early breast cancer: A systematic review and meta-analysis

European journal of cancer (1990), 2015-09, Vol.51, p.S324-S325

2015

Volltextzugriff (PDF)

2337P Feasibility of mutation detection in cytological samples from metastasis in patients with metastatic prostate cancer

Annals of oncology, 2023-10, Vol.34, p.S1192-S1192

2023

Volltextzugriff (PDF)

Assessing Women at High Risk of Breast Cancer: A Review of Risk Assessment Models

JNCI : Journal of the National Cancer Institute, 2010-05, Vol.102 (10), p.680-691

2010

Volltextzugriff (PDF)

Impact of Geographic Region on Benefit of Approved Anticancer Drugs Evaluated in International Phase III Clinical Trials

Clinical oncology (Royal College of Radiologists (Great Britain)), 2016-05, Vol.28 (5), p.283-291

2016

Volltextzugriff (PDF)

Absolute benefits of medical therapies in phase III clinical trials for breast and colorectal cancer

Annals of oncology, 2010-07, Vol.21 (7), p.1411-1418

2010

Volltextzugriff (PDF)

The changing face of hormonal therapy for prostate cancer

Annals of oncology, 2008-09, Vol.19 (suppl-7), p.vii79-vii85

2008

Volltextzugriff (PDF)

A randomized double-blind placebo-controlled cross-over trial of the impact on quality of life of continuing dexamethasone beyond 24 h following adjuvant chemotherapy for breast cancer

Breast cancer research and treatment, 2012-11, Vol.136 (1), p.143-151

2012

Volltextzugriff (PDF)

Aggressive anticancer treatment in the last 2 weeks of life

ESMO open, 2024-03, Vol.9 (3), p.102937-102937, Article 102937

2024

Volltextzugriff (PDF)

676P Prognostic role of nutritional status (NS) for health-related quality of life (HRQoL) in men with advanced prostate cancer

Annals of oncology, 2020-09, Vol.31, p.S540-S540

2020

Volltextzugriff (PDF)

111P Reporting of late serious adverse drug reactions (ADRs) in drug labels of targeted anticancer agents

ESMO open, 2024-02, Vol.9, p.102336, Article 102336

2024

Volltextzugriff (PDF)

1583O Clinical benefit of cancer drugs approved in Switzerland during the last decade

Annals of oncology, 2020-09, Vol.31, p.S961-S961

2020

Volltextzugriff (PDF)

1 – 25 von 73

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(71)
Mit Volltextzugriff
(69)

Publikationsform

Artikel
(70)
Tagungsberichte
(3)

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(30)
Life Sciences & Biomedicine
(28)
Oncology
(19)
Humans
(18)
Biological And Medical Sciences
(12)
Female
(10)
Medical Sciences
(8)
Hematology, Oncology And Palliative Medicine
(7)
Tumors
(6)
Aged
(5)
Antineoplastic Agents
(5)
Breast Cancer
(5)
Breast Neoplasms - Drug Therapy
(5)
Fundamental And Applied Biological Sciences. Psychology
(5)
Gynecology. Andrology. Obstetrics
(5)
Middle Aged
(5)
Cancer
(4)
Chemotherapy, Adjuvant
(4)
Food Science & Technology
(4)
Mammary Gland Diseases
(4)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Androgen Receptor Expression and Outcomes in Early Breast Cancer: A Systematic Review and Meta-Analysis

How valid are claims for synergy in published clinical studies?

Hyperglycaemia and Survival in Solid Tumours: A Systematic Review and Meta-analysis

Evolution in the eligibility criteria of randomized controlled trials for systemic cancer therapies

Medical Oncology Workload in Europe: One Continent, Several Worlds

Magnitude of clinical benefit in trials supporting US Food and Drug Administration (FDA) accelerated approval (AA) and European Medicines Agency (EMA) conditional marketing authorisation (CMA) and subsequent trials supporting conversion to full approval

A multimodal approach for the management of co-morbid cardiotoxicity in the elderly breast cancer patients

Medical oncology workload in Canada: infrastructure, supports, and delivery of clinical care

1229 Industry-Sponsored Posters at Major Oncology Conferences: Science or Marketing?

Association of Aromatase Inhibitors With Coronary Heart Disease in Women With Early Breast Cancer

Comparison of absolute benefits of anticancer therapies determined by snapshot and area methods

1204 Influence of companion diagnostics on efficacy and safety of targeted anti-cancer drugs

1215 Role of cooperative groups and funding source in clinical studies that support approved therapy for breast cancer

2589 Adjuvant radiation therapy after radical nephrectomy in patients with localized renal cell carcinoma: a systematic review and meta-analysis

1973 Epidermal growth factor receptor (EGFR) over-expression and outcomes in early breast cancer: A systematic review and meta-analysis

2337P Feasibility of mutation detection in cytological samples from metastasis in patients with metastatic prostate cancer

Assessing Women at High Risk of Breast Cancer: A Review of Risk Assessment Models

Impact of Geographic Region on Benefit of Approved Anticancer Drugs Evaluated in International Phase III Clinical Trials

Absolute benefits of medical therapies in phase III clinical trials for breast and colorectal cancer

The changing face of hormonal therapy for prostate cancer

A randomized double-blind placebo-controlled cross-over trial of the impact on quality of life of continuing dexamethasone beyond 24 h following adjuvant chemotherapy for breast cancer

Aggressive anticancer treatment in the last 2 weeks of life

676P Prognostic role of nutritional status (NS) for health-related quality of life (HRQoL) in men with advanced prostate cancer

111P Reporting of late serious adverse drug reactions (ADRs) in drug labels of targeted anticancer agents

1583O Clinical benefit of cancer drugs approved in Switzerland during the last decade

Suchergebnisse filtern